Skip to content
TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
-$309.44M-7.3%-$288.28M+0.3%-$289.13M-2.6%-$281.9M+28.0%-$391.59M+15.9%
$1.51M+0.5%$1.51M+2.0%$1.48M+4.2%$1.42M+8.4%$1.31M+19.3%
$111.22M+13.3%$98.13M+9.0%$90.02M+10.2%$81.66M+0.9%$80.91M+1.3%
-$307.41M+22.2%-$395.31M+13.2%
$1.05M+8.0%$974K-11.9%$1.11M-24.4%
-$38.61M+81.5%-$208.56M+24.0%
$249.67M-2.5%$255.98M-4.1%$266.8M+609%$37.61M-77.9%$170M-76.9%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Madrigal Pharmaceuticals, Inc. generate?
Madrigal Pharmaceuticals, Inc. (MDGL) generated -$436.8M in operating cash flow over the trailing twelve months.
What is Madrigal Pharmaceuticals, Inc.'s free cash flow?
After $4.7M of capital expenditures, Madrigal Pharmaceuticals, Inc.'s free cash flow was -$440.3M over the trailing twelve months, up 3.7% year over year.
Where does Madrigal Pharmaceuticals, Inc.'s cash flow data come from?
Every line is extracted from Madrigal Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.